(SKWD) Skyward Specialty Insurance - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8309401029
Stock: Liability, Property, Auto, Workers Comp, Specialty
Total Rating 40
Risk 73
Buy Signal 0.21
| Risk 5d forecast | |
|---|---|
| Volatility | 34.6% |
| Relative Tail Risk | -3.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.02 |
| Alpha | -16.48 |
| Character TTM | |
|---|---|
| Beta | 0.468 |
| Beta Downside | 0.997 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.15% |
| CAGR/Max DD | 1.10 |
EPS (Earnings per Share)
Revenue
Description: SKWD Skyward Specialty Insurance March 05, 2026
Skyward Specialty Insurance Group, Inc. (SKWD) is a U.S.-based insurance holding company. It underwrites commercial property and casualty insurance.
The company offers a diverse portfolio of insurance products. These include general liability, excess liability, professional liability, and commercial auto insurance. It also provides specialized coverage such as cannabis insurance, a niche within the broader insurance market.
SKWD operates in the Property & Casualty Insurance sector, a segment of the financial industry focused on protecting businesses and individuals from financial losses due to property damage, liability claims, and other covered perils. The company was incorporated in 2006 and is headquartered in Houston, Texas.
For more in-depth data and analytics, explore ValueRay.
Headlines to watch out for
Commercial property insurance demand impacts premium growth | Catastrophic weather events increase claims payouts | Interest rate changes affect investment income | Regulatory changes influence underwriting profitability | Competition in specialty insurance markets pressures pricing
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 170.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -2.88 > 1.0 |
| NWC/Revenue: 85.28% < 20% (prev 188.2%; Δ -102.9% < -1%) |
| CFO/TA 0.08 > 3% & CFO 378.2m > Net Income 170.0m |
| Net Debt (-68.1m) to EBITDA (223.6m): -0.30 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.9m) vs 12m ago 0.60% < -2% |
| Gross Margin: 34.23% > 18% (prev 0.29%; Δ 3394 % > 0.5%) |
| Asset Turnover: 33.31% > 50% (prev 30.77%; Δ 2.53% > 0%) |
| Interest Coverage Ratio: 28.33 > 6 (EBITDA TTM 223.6m / Interest Expense TTM 7.92m) |
Altman Z'' 2.27
| A: 0.25 (Total Current Assets 2.57b - Total Current Liabilities 1.36b) / Total Assets 4.79b |
| B: 0.06 (Retained Earnings 267.1m / Total Assets 4.79b) |
| C: 0.05 (EBIT TTM 224.3m / Avg Total Assets 4.26b) |
| D: 0.07 (Book Value of Equity 279.0m / Total Liabilities 3.78b) |
| Altman-Z'' Score: 2.27 = BBB |
Beneish M
| DSRI: 0.37 (Receivables 544.2m/1.18b, Revenue 1.42b/1.15b) |
| GMI: 0.83 (GM 34.23% / 28.57%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.24 (Revenue 1.42b / 1.15b) |
| TATA: -0.04 (NI 170.0m - CFO 378.2m) / TA 4.79b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of SKWD shares?
As of March 08, 2026, the stock is trading at USD 48.71 with a total of 465,060 shares traded.
Over the past week, the price has changed by +4.82%, over one month by +10.75%, over three months by +4.17% and over the past year by -1.77%.
Over the past week, the price has changed by +4.82%, over one month by +10.75%, over three months by +4.17% and over the past year by -1.77%.
Is SKWD a buy, sell or hold?
Skyward Specialty Insurance has received a consensus analysts rating of 3.83.
Therefore, it is recommended to buy SKWD.
- StrongBuy: 3
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SKWD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 60.3 | 23.7% |
| Analysts Target Price | 60.3 | 23.7% |
SKWD Fundamental Data Overview March 08, 2026
P/E Trailing = 13.7893
P/E Forward = 9.6432
P/S = 1.4489
P/B = 2.1348
P/EG = 0.7245
Revenue TTM = 1.42b USD
EBIT TTM = 224.3m USD
EBITDA TTM = 223.6m USD
Long Term Debt = 76.6m USD (from longTermDebt, two quarters ago)
Short Term Debt = 43.0m USD (from shortTermDebt, two quarters ago)
Debt = 100.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -68.1m USD (from netDebt column, last quarter)
Enterprise Value = 128.0m USD (2.05b + Debt 100.4m - CCE 2.02b)
Interest Coverage Ratio = 28.33 (Ebit TTM 224.3m / Interest Expense TTM 7.92m)
EV/FCF = 0.34x (Enterprise Value 128.0m / FCF TTM 371.4m)
FCF Yield = 290.2% (FCF TTM 371.4m / Enterprise Value 128.0m)
FCF Margin = 26.17% (FCF TTM 371.4m / Revenue TTM 1.42b)
Net Margin = 11.98% (Net Income TTM 170.0m / Revenue TTM 1.42b)
Gross Margin = 34.23% ((Revenue TTM 1.42b - Cost of Revenue TTM 933.4m) / Revenue TTM)
Gross Margin QoQ = 44.84% (prev 31.18%)
Tobins Q-Ratio = 0.03 (Enterprise Value 128.0m / Total Assets 4.79b)
Interest Expense / Debt = 2.28% (Interest Expense 2.29m / Debt 100.4m)
Taxrate = 20.89% (11.4m / 54.6m)
NOPAT = 177.5m (EBIT 224.3m * (1 - 20.89%))
Current Ratio = 1.89 (Total Current Assets 2.57b / Total Current Liabilities 1.36b)
Debt / Equity = 0.10 (Debt 100.4m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -0.30 (Net Debt -68.1m / EBITDA 223.6m)
Debt / FCF = -0.18 (Net Debt -68.1m / FCF TTM 371.4m)
Total Stockholder Equity = 930.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.99% (Net Income 170.0m / Total Assets 4.79b)
RoE = 18.27% (Net Income TTM 170.0m / Total Stockholder Equity 930.4m)
RoCE = 22.28% (EBIT 224.3m / Capital Employed (Equity 930.4m + L.T.Debt 76.6m))
RoIC = 17.34% (NOPAT 177.5m / Invested Capital 1.02b)
WACC = 7.37% (E(2.05b)/V(2.15b) * Re(7.64%) + D(100.4m)/V(2.15b) * Rd(2.28%) * (1-Tc(0.21)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.85%
[DCF] Terminal Value 83.35% ; FCFF base≈381.5m ; Y1≈470.5m ; Y5≈801.4m
[DCF] Fair Price = 353.0 (EV 15.52b - Net Debt -68.1m = Equity 15.59b / Shares 44.2m; r=7.37% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 96.10 | EPS CAGR: 47.61% | SUE: 2.86 | # QB: 5
Revenue Correlation: 98.34 | Revenue CAGR: 30.17% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.23 | Chg7d=+0.034 | Chg30d=+0.037 | Revisions Net=+1 | Analysts=9
EPS current Year (2026-12-31): EPS=4.87 | Chg7d=+0.059 | Chg30d=+0.072 | Revisions Net=+2 | Growth EPS=+21.7% | Growth Revenue=+27.7%
EPS next Year (2027-12-31): EPS=5.47 | Chg7d=+0.021 | Chg30d=+0.016 | Revisions Net=+2 | Growth EPS=+12.3% | Growth Revenue=+12.8%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.7% (Discount Rate 7.9% - Earnings Yield 7.3%)
[Growth] Growth Spread = +37.8% (Analyst 38.5% - Implied 0.7%)
P/E Forward = 9.6432
P/S = 1.4489
P/B = 2.1348
P/EG = 0.7245
Revenue TTM = 1.42b USD
EBIT TTM = 224.3m USD
EBITDA TTM = 223.6m USD
Long Term Debt = 76.6m USD (from longTermDebt, two quarters ago)
Short Term Debt = 43.0m USD (from shortTermDebt, two quarters ago)
Debt = 100.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -68.1m USD (from netDebt column, last quarter)
Enterprise Value = 128.0m USD (2.05b + Debt 100.4m - CCE 2.02b)
Interest Coverage Ratio = 28.33 (Ebit TTM 224.3m / Interest Expense TTM 7.92m)
EV/FCF = 0.34x (Enterprise Value 128.0m / FCF TTM 371.4m)
FCF Yield = 290.2% (FCF TTM 371.4m / Enterprise Value 128.0m)
FCF Margin = 26.17% (FCF TTM 371.4m / Revenue TTM 1.42b)
Net Margin = 11.98% (Net Income TTM 170.0m / Revenue TTM 1.42b)
Gross Margin = 34.23% ((Revenue TTM 1.42b - Cost of Revenue TTM 933.4m) / Revenue TTM)
Gross Margin QoQ = 44.84% (prev 31.18%)
Tobins Q-Ratio = 0.03 (Enterprise Value 128.0m / Total Assets 4.79b)
Interest Expense / Debt = 2.28% (Interest Expense 2.29m / Debt 100.4m)
Taxrate = 20.89% (11.4m / 54.6m)
NOPAT = 177.5m (EBIT 224.3m * (1 - 20.89%))
Current Ratio = 1.89 (Total Current Assets 2.57b / Total Current Liabilities 1.36b)
Debt / Equity = 0.10 (Debt 100.4m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -0.30 (Net Debt -68.1m / EBITDA 223.6m)
Debt / FCF = -0.18 (Net Debt -68.1m / FCF TTM 371.4m)
Total Stockholder Equity = 930.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.99% (Net Income 170.0m / Total Assets 4.79b)
RoE = 18.27% (Net Income TTM 170.0m / Total Stockholder Equity 930.4m)
RoCE = 22.28% (EBIT 224.3m / Capital Employed (Equity 930.4m + L.T.Debt 76.6m))
RoIC = 17.34% (NOPAT 177.5m / Invested Capital 1.02b)
WACC = 7.37% (E(2.05b)/V(2.15b) * Re(7.64%) + D(100.4m)/V(2.15b) * Rd(2.28%) * (1-Tc(0.21)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.85%
[DCF] Terminal Value 83.35% ; FCFF base≈381.5m ; Y1≈470.5m ; Y5≈801.4m
[DCF] Fair Price = 353.0 (EV 15.52b - Net Debt -68.1m = Equity 15.59b / Shares 44.2m; r=7.37% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 96.10 | EPS CAGR: 47.61% | SUE: 2.86 | # QB: 5
Revenue Correlation: 98.34 | Revenue CAGR: 30.17% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.23 | Chg7d=+0.034 | Chg30d=+0.037 | Revisions Net=+1 | Analysts=9
EPS current Year (2026-12-31): EPS=4.87 | Chg7d=+0.059 | Chg30d=+0.072 | Revisions Net=+2 | Growth EPS=+21.7% | Growth Revenue=+27.7%
EPS next Year (2027-12-31): EPS=5.47 | Chg7d=+0.021 | Chg30d=+0.016 | Revisions Net=+2 | Growth EPS=+12.3% | Growth Revenue=+12.8%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.7% (Discount Rate 7.9% - Earnings Yield 7.3%)
[Growth] Growth Spread = +37.8% (Analyst 38.5% - Implied 0.7%)